{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:57:53Z","timestamp":1791046673121,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.semarthrit.2005.01.003","type":"journal-article","created":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T16:59:55Z","timestamp":1113411595000},"page":"7-11","source":"Crossref","is-referenced-by-count":55,"special_numbering":"S1","title":["Differentiating the efficacy of the tumor necrosis factor inhibitors"],"prefix":"10.1016","volume":"34","author":[{"given":"Boulos","family":"Haraoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2005.01.003_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2005.01.003_bib5","first-page":"S77","article-title":"Global safety and efficacy of up to five years of etanercept therapy","volume":"44","author":"Klareskog","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib8","first-page":"S269","article-title":"102-wk clinical and radiologic results from the ATTRACT trial","volume":"43","author":"Lipsky","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib9","series-title":"Infliximab dose and clinical status in 1,248 RA patients seen in rheumatology clinical practice","author":"Wolfe","year":"2003"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib10","first-page":"2525","article-title":"The use of infliximab in academic rheumatology practice","volume":"29","author":"Fitzcharles","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib12","first-page":"2563","article-title":"Adalimumab, a fully human anti-tumor necrosis factor-\u03b1 monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib13","first-page":"1836","article-title":"Switch \u00e9tanercept-onfliximab dans la paolyarthrite rhumato\u00efde","volume":"31","author":"Brocq","year":"2002","journal-title":"Presse Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab when etanercept has failed or vice versa","volume":"62","author":"Van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib15","first-page":"2315","article-title":"Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other TNF\u03b1 antagonists in patients with rheumatoid arthritis","volume":"30","author":"Ang","year":"2003","journal-title":"J Rheumatol"},{"issue":"9S","key":"10.1016\/j.semarthrit.2005.01.003_bib16","first-page":"S701","article-title":"Understanding non-response to infliximab","volume":"48","author":"Buch","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","article-title":"Patterns of expression of tumor necrosis factor \u03b1, tumor necrosis factor \u03b2, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy","volume":"39","author":"Grom","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2249.1994.tb06551.x","article-title":"Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis","volume":"96","author":"Eberhard","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib19","series-title":"Enbrel\u00ae (etanercept) Prescribing Information","year":"2003"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib20","series-title":"Remicade\u00ae (infliximab) Prescribing Information","year":"2003"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib21","first-page":"2356","article-title":"Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept","volume":"31","author":"Haraoui","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib22","series-title":"Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study","author":"Wagner","year":"2002"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib27","series-title":"Efficacy of infusions of an anti-TNF\u03b1 antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis","author":"Gerloni","year":"2003"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"9S","key":"10.1016\/j.semarthrit.2005.01.003_bib29","first-page":"S169","article-title":"Continued efficacy and safety of etanercept (ENBREL\u00ae) in patients with psoriatic arthritis and psoriasis","volume":"48","author":"Mease","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9S","key":"10.1016\/j.semarthrit.2005.01.003_bib30","first-page":"S121","article-title":"Treatment of psoriatic arthritis with infliximab in a small office-based rheumatology practice","volume":"44","author":"Bolce","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9S","key":"10.1016\/j.semarthrit.2005.01.003_bib31","first-page":"S121","article-title":"Emerging role for infliximab in psoriatic arthritis patients resistant to DMARDs","volume":"44","author":"Bray","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib33","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib34","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"9S","key":"10.1016\/j.semarthrit.2005.01.003_bib35","first-page":"S383","article-title":"Infliximab monotherapy in the treatment of plaque-type psoriasis","volume":"44","author":"Gottlieb","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib36","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib39","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00000441-200302000-00005","article-title":"New indications for treatment of chronic inflammation by TNF-\u03b1 blockade","volume":"325","author":"Reimold","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib45","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway","volume":"121","author":"L\u00fcgering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2005.01.003_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0016-5085(99)70177-0","article-title":"Lamina propria T cells in Crohn\u2019s disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis","volume":"116","author":"Boirivant","year":"1999","journal-title":"Gastroenterology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017205000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017205000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T11:28:45Z","timestamp":1548588525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017205000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0049017205000041"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}